Startup aims to churn out other orphan drug startups

04/25/2013 | Xconomy

Armed with $16 million in venture capital, former MedImmune boss David Mott's new enterprise Cydan will find and fund small firms with promising orphan drug candidates. Investor return will be through licensing deals with or acquisition by larger drugmakers. Mott plans to collaborate with parent and patient advocacy groups and will subcontract toxicology, pharmacology and other testing to reduce development risk.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA